We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed at $79.31 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily gain of 0.77%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.95%.
The pharmaceutical's shares have seen an increase of 3.5% over the last month, surpassing the Medical sector's gain of 1.49% and falling behind the S&P 500's gain of 3.71%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.98, reflecting a 9.26% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.49 billion, indicating a 9.4% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.04 per share and a revenue of $51.78 billion, indicating changes of +11.29% and +13.03%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.25% higher within the past month. Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 19.72. This indicates a premium in contrast to its industry's Forward P/E of 14.54.
One should further note that AZN currently holds a PEG ratio of 1.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 149, placing it within the bottom 41% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Sinks As Market Gains: Here's Why
Astrazeneca (AZN - Free Report) closed at $79.31 in the latest trading session, marking a -0.35% move from the prior day. This move lagged the S&P 500's daily gain of 0.77%. At the same time, the Dow added 0.49%, and the tech-heavy Nasdaq gained 0.95%.
The pharmaceutical's shares have seen an increase of 3.5% over the last month, surpassing the Medical sector's gain of 1.49% and falling behind the S&P 500's gain of 3.71%.
Analysts and investors alike will be keeping a close eye on the performance of Astrazeneca in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.98, reflecting a 9.26% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.49 billion, indicating a 9.4% increase compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.04 per share and a revenue of $51.78 billion, indicating changes of +11.29% and +13.03%, respectively, from the former year.
Investors should also pay attention to any latest changes in analyst estimates for Astrazeneca. Recent revisions tend to reflect the latest near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.25% higher within the past month. Astrazeneca is holding a Zacks Rank of #3 (Hold) right now.
With respect to valuation, Astrazeneca is currently being traded at a Forward P/E ratio of 19.72. This indicates a premium in contrast to its industry's Forward P/E of 14.54.
One should further note that AZN currently holds a PEG ratio of 1.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 149, placing it within the bottom 41% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.